{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T20:37:10Z","timestamp":1770842230395,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1038\/s41375-024-02236-4","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T13:01:55Z","timestamp":1712235715000},"page":"1287-1298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["I\u03baB\u03b5 deficiency accelerates disease development in chronic lymphocytic leukemia"],"prefix":"10.1038","volume":"38","author":[{"given":"Jessica","family":"Bordini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Lenzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Frenquelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2313-6748","authenticated-orcid":false,"given":"Alessia","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athanasios","family":"Pseftogas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Belloni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Tsiolas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleonora","family":"Perotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Ranghetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8930-8295","authenticated-orcid":false,"given":"Francesca","family":"Gandini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7470-6386","authenticated-orcid":false,"given":"Francesca","family":"Genova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7270-0776","authenticated-orcid":false,"given":"Daniel","family":"H\u00e4gerstrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Gavriilidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofoklis","family":"Keisaris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Pechlivanis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederic","family":"Davi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5951-5055","authenticated-orcid":false,"given":"Neil E.","family":"Kay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2078-3220","authenticated-orcid":false,"given":"Anton W.","family":"Langerak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarka","family":"Pospisilova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0844-0989","authenticated-orcid":false,"given":"Lydia","family":"Scarf\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonios","family":"Makris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0222-4273","authenticated-orcid":false,"given":"Fotis E.","family":"Psomopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kostas","family":"Stamatopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0211-8788","authenticated-orcid":false,"given":"Richard","family":"Rosenquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3463-1199","authenticated-orcid":false,"given":"Alessandro","family":"Campanella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3750-7342","authenticated-orcid":false,"given":"Paolo","family":"Ghia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,4]]},"reference":[{"key":"2236_CR1","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.semcancer.2015.04.009","volume":"34","author":"LA Sutton","year":"2015","unstructured":"Sutton LA, Rosenquist R. The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia. Semin Cancer Biol. 2015;34:22\u201335.","journal-title":"Semin Cancer Biol"},{"key":"2236_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.semcancer.2016.07.005","volume":"39","author":"L Mansouri","year":"2016","unstructured":"Mansouri L, Papakonstantinou N, Ntoufa S, Stamatopoulos K, Rosenquist R. NF-\u03baB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions. Semin Cancer Biol. 2016;39:40\u20138.","journal-title":"Semin Cancer Biol"},{"key":"2236_CR3","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.3324\/haematol.2019.236000","volume":"105","author":"J Delgado","year":"2020","unstructured":"Delgado J, Nadeu F, Colomer D, Campo E. Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies. Haematologica. 2020;105:2205\u201317.","journal-title":"Haematologica"},{"key":"2236_CR4","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1084\/jem.20142009","volume":"212","author":"L Mansouri","year":"2015","unstructured":"Mansouri L, Sutton LA, Ljungstr\u00f6m V, Bondza S, Arng\u00e5rden L, Bhoi S, et al. Functional loss of I\u03baB\u03b5 leads to NF-\u03baB deregulation in aggressive chronic lymphocytic leukemia. J Exp Med. 2015;212:833\u201343.","journal-title":"J Exp Med"},{"key":"2236_CR5","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1158\/2159-8290.CD-14-0104","volume":"4","author":"F Damm","year":"2014","unstructured":"Damm F, Mylonas E, Cosson A, Yoshida K, Della Valle V, Mouly E, et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov. 2014;4:1088\u2013101.","journal-title":"Cancer Discov"},{"key":"2236_CR6","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1038\/s41588-022-01211-y","volume":"54","author":"P Robbe","year":"2022","unstructured":"Robbe P, Ridout KE, Vavoulis DV, Dr\u00e9au H, Kinnersley B, Denny N, et al. Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features. Nat Genet. 2022;54:1675\u201389.","journal-title":"Nat Genet"},{"key":"2236_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0305-6","volume":"10","author":"V Della-Valle","year":"2020","unstructured":"Della-Valle V, Roos-Weil D, Scourzic L, Mouly E, Aid Z, Darwiche W, et al. Nfkbie-deficiency leads to increased susceptibility to develop B-cell lymphoproliferative disorders in aged mice. Blood Cancer J. 2020;10:38.","journal-title":"Blood Cancer J"},{"key":"2236_CR8","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41375-022-01802-y","volume":"37","author":"Mansouri","year":"2023","unstructured":"Mansouri, Thorvaldsdottir L, Sutton LA B, Karakatsoulis G, Meggendorfer M, Parker H, et al. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY. Leukemia. 2023;37:339\u201347.","journal-title":"Leukemia"},{"key":"2236_CR9","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.4049\/jimmunol.1302351","volume":"192","author":"BN Alves","year":"2014","unstructured":"Alves BN, Tsui R, Almaden J, Shokhirev MN, Davis-Turak J, Fujimoto J, et al. I\u03baB\u03b5 is a key regulator of B cell expansion by providing negative feedback on cRel and RelA in a stimulus-specific manner. J Immunol. 2014;192:3121\u201332.","journal-title":"J Immunol"},{"key":"2236_CR10","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.3324\/haematol.2020.248112","volume":"106","author":"F Barbaglio","year":"2021","unstructured":"Barbaglio F, Belloni D, Scarf\u00f2 L, Sbrana FV, Ponzoni M, Bongiovanni L, et al. Three-dimensional co-culture model of chronic lymphocytic leukemia bone marrow microenvironment predicts patient-specific response to mobilizing agents. Haematologica. 2021;106:2334\u201344.","journal-title":"Haematologica"},{"key":"2236_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2022.101601","volume":"3","author":"D Belloni","year":"2022","unstructured":"Belloni D, Ferrarini M, Ferrero E, Guzzeloni V, Barbaglio F, Ghia P, et al. Protocol for generation of 3D bone marrow surrogate microenvironments in a rotary cell culture system. STAR Protoc. 2022;3:101601.","journal-title":"STAR Protoc"},{"key":"2236_CR12","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1182\/blood-2009-05-223586","volume":"115","author":"MTS Bertilaccio","year":"2010","unstructured":"Bertilaccio MTS, Scielzo C, Simonetti G, Ponzoni M, Apollonio B, Fazi C, et al. A novel Rag2\u2212\/\u2212\u03b3c\u2212\/\u2212xenograft model of human CLL. Blood. 2010;115:1605\u20139.","journal-title":"Blood"},{"key":"2236_CR13","doi-asserted-by":"publisher","first-page":"33508","DOI":"10.1074\/jbc.273.50.33508","volume":"273","author":"G Ly","year":"1998","unstructured":"Ly G, Knorre A, Schmidt TJ, Pahl HL, Merfort I. The anti-inflammatory sesquiterpene lactone helenalin inhibits the transcription factor NF-\u03baB by directly targeting p65. J Biol Chem. 1998;273:33508\u201316.","journal-title":"J Biol Chem"},{"key":"2236_CR14","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3727\/096504020X15929100013698","volume":"28","author":"K Umezawa","year":"2020","unstructured":"Umezawa K, Breborowicz A, Gantsev S. Anticancer Activity of Novel NF-kappa B Inhibitor DHMEQ by Intraperitoneal Administration. Oncol Res. 2020;28:541\u201350.","journal-title":"Oncol Res"},{"key":"2236_CR15","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1182\/bloodadvances.2022008821","volume":"7","author":"S Bonfiglio","year":"2023","unstructured":"Bonfiglio S, Sutton LA, Ljungstr\u00f6m V, Capasso A, Pandzic T, Westr\u00f6m S, et al. BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib. Blood Adv. 2023;7:2794\u2013806.","journal-title":"Blood Adv"},{"key":"2236_CR16","doi-asserted-by":"publisher","first-page":"26019","DOI":"10.18632\/oncotarget.25419","volume":"9","author":"D Primo","year":"2018","unstructured":"Primo D, Scarf\u00f2 L, Xochelli A, Mattsson M, Ranghetti P, Espinosa AB, et al. A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia. Oncotarget. 2018;9:26019\u201331.","journal-title":"Oncotarget"},{"key":"2236_CR17","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1182\/blood-2018-09-876292","volume":"133","author":"PE Morande","year":"2019","unstructured":"Morande PE, Sivina M, Uriepero A, Seija N, Berca C, Fresia P, et al. Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia. Blood. 2019;133:2056\u201368.","journal-title":"Blood"},{"key":"2236_CR18","doi-asserted-by":"publisher","first-page":"6955","DOI":"10.1073\/pnas.102181599","volume":"99","author":"R Bichi","year":"2002","unstructured":"Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA. 2002;99:6955\u201360.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2236_CR19","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1182\/blood-2005-12-011213","volume":"108","author":"AJ Johnson","year":"2006","unstructured":"Johnson AJ, Lucas DM, Muthusamy N, Smith LL, Edwards RB, De Lay MD, et al. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood. 2006;108:1334\u20138.","journal-title":"Blood"},{"key":"2236_CR20","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1038\/s41375-018-0335-2","volume":"33","author":"M Gounari","year":"2019","unstructured":"Gounari M, Ntoufa S, Gerousi M, Vilia MG, Moysiadis T, Kotta K, et al. Dichotomous Toll-like receptor responses in chronic lymphocytic leukemia patients under ibrutinib treatment. Leukemia. 2019;33:1030\u201351.","journal-title":"Leukemia"},{"key":"2236_CR21","doi-asserted-by":"crossref","unstructured":"di Bergamo LT, Forestieri G, Loh JW, Singh A, Spina V, Zucchetto A, et al. Adaptation of chronic lymphocytic leukemia to ibrutinib is mediated by epigenetic plasticity of residual disease and bypass signaling via the MAPK pathway. Clin Lymphoma Myeloma Leuk. 2021;21:S323\u20134.","DOI":"10.1016\/S2152-2650(21)01761-4"},{"key":"2236_CR22","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1182\/blood-2013-09-527853","volume":"123","author":"JA Woyach","year":"2014","unstructured":"Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123:1810\u20137.","journal-title":"Blood"},{"key":"2236_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/sigtrans.2017.23","volume":"2","author":"T Liu","year":"2017","unstructured":"Liu T, Zhang L, Joo D, Sun SC. NF-\u03baB signaling in inflammation. Signal Transduct Target Ther. 2017;2:17023.","journal-title":"Signal Transduct Target Ther"},{"key":"2236_CR24","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","volume":"117","author":"Y Herishanu","year":"2011","unstructured":"Herishanu Y, P\u00e9rez-Gal\u00e1n P, Liu D, Biancotto A, Pittaluga S, Vire B, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117:563\u201374.","journal-title":"Blood"},{"key":"2236_CR25","doi-asserted-by":"publisher","first-page":"e38158","DOI":"10.1371\/journal.pone.0038158","volume":"7","author":"E Dom\u00e9nech","year":"2012","unstructured":"Dom\u00e9nech E, G\u00f3mez-L\u00f3pez G, Gzlez-Pe\u00f1a D, L\u00f3pez M, Herreros B, Menezes J, et al. New mutations in chronic lymphocytic leukemia identified by target enrichment and deep sequencing. PloS One. 2012;7:e38158.","journal-title":"PloS One"},{"key":"2236_CR26","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/leu.2016.10","volume":"30","author":"MJJ Rose-Zerilli","year":"2016","unstructured":"Rose-Zerilli MJJ, Gibson J, Wang J, Tapper W, Davis Z, Parker H, et al. Longitudinal copy number, whole exome and targeted deep sequencing of \u201cgood risk\u201d IGHV-mutated CLL patients with progressive disease. Leukemia. 2016;30:1301\u201310.","journal-title":"Leukemia"},{"key":"2236_CR27","doi-asserted-by":"publisher","first-page":"113017","DOI":"10.1016\/j.celrep.2023.113017","volume":"42","author":"V Ecker","year":"2023","unstructured":"Ecker V, Brandmeier L, Stumpf M, Giansanti P, Moreira AV, Pfeuffer L, et al. Negative feedback regulation of MAPK signaling is an important driver of chronic lymphocytic leukemia progression. Cell Rep. 2023;42:113017.","journal-title":"Cell Rep"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02236-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02236-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02236-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T12:04:04Z","timestamp":1717416244000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02236-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,4]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["2236"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02236-4","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,4]]},"assertion":[{"value":"4 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"PG: honoraria\/advisory board: AbbVie, Acerta\/AstraZeneca, Adaptive, ArQule\/MSD, BeiGene, CelGene\/Juno, Gilead, Janssen, Loxo\/Lilly, Sunesis; research funding: AbbVie, Gilead, Janssen, Novartis, Sunesis. RR: honoraria\/advisory board: Abbvie, AstraZeneca, Janssen, Illumina and Roche. KS: honoraria\/advisory board: AbbVie, Acerta\/AstraZeneca, Gilead, Janssen; research funding: AbbVie, Gilead, Janssen.; NEK: Advisory Board for: AbbVie, Astra Zeneca, Beigene, Behring, Boehringer Ingelheim Pharmaceuticals, Inc., Dava Oncology, Janssen, Juno Therapeutics, Pharmacyclics. DSMC (Data Safety Monitoring Committee) for: Agios Pharm, AstraZeneca, BMS \u2013Celgene, Dren Bio Janssen,. Research funding from: AbbVie, Acerta Pharma, Bristol Meyer Squib, Celgene, Genentech, Pharmacyclics, Sunesis, Vincerx.; LS: advisory board: AbbVie, AstraZeneca, Janssen.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}